Why has the success rate of insitro's cell-based assays for drug discovery dropped by 20% compared to the previous quarter?

Introduction

The recent 20% drop in the success rate of insitro's cell-based assays for drug discovery is a critical issue that demands immediate attention. This decline not only impacts the efficiency of our drug discovery process but also has potential ripple effects on our overall R&D pipeline and company performance. To address this complex problem, I'll employ a systematic approach to identify, validate, and resolve the root cause while considering both short-term fixes and long-term strategic implications.

Step 1

Clarifying Questions (3 minutes)

• Looking at the timing, I'm thinking there might have been recent changes to our assay protocols. Have we implemented any new procedures or modified existing ones in the past quarter?

Why it matters: Changes in protocols could directly impact assay performance. Expected answer: Yes, we've updated our cell culture media. Impact on approach: If confirmed, we'd focus on validating the new media's effects on cell viability and assay outcomes.

• Considering the scale of the drop, I'm wondering about our quality control processes. Have we noticed any changes in the consistency or quality of our reagents or cell lines?

Why it matters: Inconsistent inputs could lead to variable assay results. Expected answer: No significant changes reported in QC logs. Impact on approach: If true, we'd shift focus to other potential causes like equipment or environmental factors.

• Given the complexity of cell-based assays, I'm curious about our data analysis pipeline. Has there been any update to our data processing algorithms or thresholds for success?

Why it matters: Changes in data interpretation could artificially inflate the perceived drop in success rate. Expected answer: Minor updates to analysis software, but no major changes to success criteria. Impact on approach: If confirmed, we'd need to validate the impact of these updates on our success rate calculations.

• Thinking about external factors, I'm wondering if there have been any changes in the types of drug targets or compound libraries we're screening.

Why it matters: Different targets or compound classes could have inherently different success rates. Expected answer: We've recently started focusing on a new class of challenging targets. Impact on approach: If true, we'd need to adjust our expectations and potentially optimize our assays for these new targets.